DelveInsight’s ‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the BRAF Mutated NSCLC, historical and forecasted epidemiology as well as the BRAF Mutated NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The BRAF Mutated NSCLC market report provides current treatment practices, emerging drugs, BRAF Mutated NSCLC market share of the individual therapies, current and forecasted BRAF Mutated NSCLC market size from 2017 to 2030 segmented by seven major fmarkets. The Report also covers current BRAF Mutated NSCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017–2030
BRAF Mutated NSCLC Overview
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1 , BRAF , BRAF , PD-L1 expression and others. Among all the mutations BRAF accounted for approximately 5% of the total cases of NSCLC.
BRAF mutated NSCLC is now recognized as a rare form of lung cancer. The biologic behavior of BRAF mutated lung tumors tends to be more aggressive. The one unique aspects of BRAF mutated NSCLC, which differentiates it from other molecularly driven tumors such as EGFR, ALK, and ROS1, is that patients with BRAF V600E-mutant NSCLC tend to be patients with a smoking history. The BRAF gene encodes for a serine/threonine kinase that belongs to the RAS-RAF-MEK-ERK axis that regulates cellular growth.
BRAF Mutated NSCLC Diagnosis
For diagnosis of mutation associated with NSCLC a laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC.
BRAF Mutated NSCLC Treatment
There is only single US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved product is present for the treatment of BRAF mutated NSCLC, i.e., dabrafenib and trametinib combination. Current treatment choices for BRAF mutated NSCLC includes targeted therapies, platinum based chemotherapy and off-label therapies.
The BRAF mutated NSCLC epidemiology division provides the insights about historical and current BRAF Mutated NSCLC patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total incident cases of BRAF mutated NSCLC in the 7MM were found to be 19,275 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted BRAF mutated NSCLC epidemiology [segmented as Total Incident Cases of NSCLC, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total NSCLC Cases of Patients by Genetic mutation/Biomarkers, and Treated Patient Pool of NSCLC] scenario of BRAF mutated NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Country Wise- BRAF Mutated NSCLC Epidemiology
Estimates shows that the highest incident population of BRAF mutated NSCLC were in the United States, followed by Germany, United Kingdom, and France in 2017.
Drug chapter segment of the BRAF Mutated NSCLC report encloses the detailed analysis of BRAF Mutated NSCLC marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the BRAF Mutated NSCLC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
BRAF Mutated NSCLC Marketed Drugs
Tafinlar (dabrafenib) in combination with Mekinist (trametinib): Novartis Pharmaceuticals
Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib)is indicated for the treatment BRAFV600E mutationin various types of cancers. This combination is approved for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by an FDA-approved test.In addition to this, this combination is also use in patients with stage III resectable, unresectable or metastatic melanoma who have a BRAF V600 mutation.
Tafinlar is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.
In June 2017, the US FDA approved Tafinlar and Mekinist for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by a USFDA approved test. These approvals are the first specifically for the treatment of patients with BRAF V600E–mutant metastatic NSCLC. Also in In April 2017, the EC has approved Tafinlar in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic NSCLC.
In 2015, the US FDA has granted Breakthrough Therapy designation for the combination of dabrafenib and trametinib for the treatment of patients with advanced and metastatic BRAF V600E mutation-positive NSCLC who received at least one prior line of platinum-containing therapy
Products detail in the report…
BRAF Mutated NSCLC Emerging Drugs
Braftovi (encorafenib) plus Mektovi (binimetinib): Pfizer
Braftovi (encorafenib) plus Mektovi (binimetinib) combination is currently under investigation in phase II clinical trial by the Pfizer. This combination is already approved for unresectable or metastatic melanoma with a BRAFV-600E or BRAFV-600K mutation in the United States. Braftovi is an oral small molecule BRAF kinase inhibitor and Mektovi (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway.
Products detail in the report…
Enfortumab Vedotin: Astellas Pharma/ Seattle Genetics
Enfortumab Vedotin is under development by Astellas Pharma in collaboration with Seattle Genetics. It is first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4. Currently it is being investigated in phase II clinical trial for NSCLC.
Products detail in the report…
Current treatment choices for BRAF mutated NSCLC includes targeted therapies, platinum based chemotherapy and off-label therapies. However there is only one approved therapy present for the treatment of BRAF mutated i.e., Tafinlar (dabrafenib) plus Mekinist (trametinib).
On the other hand due to lack of approved therapies among all the predicted treatment choices, chemotherapies would remain an important aspect of NSCLC treatment, with platinum-based regimens being crucial. However, in future the use of platinum based chemotherapy is expected to decline because of development of therapies specifically targeting BRAF mutation.
As in the market, only one approved therapy is available, so off-label therapies such as vemurafenib and combinations and others are also used in the treatment of BRAF mutated NSCLC. Also Vemurafenib and Cobimetinib in combination are being investigated in phase II clinical trial for BRAF and other types of mutated NSCLC. So, the treatment paradigm of BRAF mutated NSCLC is developing and several efforts are ongoing for the development of treatment.
According to the expert insights, there is very limited data available about the specific efficacy of immunotherapy and chemoimmunotherapy for BRAF mutated patients. Based on that experts tend to favor targeted therapy for these patients. Several problems associated with this type of mutation for NSCLC one of them is resistance towards targeted therapy.
In BRAF mutated NSCLC after failure of dabrafenib-trametinib, there’s really not a second-line targeted-therapy approach that can be used for the treatment. Also the knowledge about mechanisms of resistance is very little. So, there is a desperate need of next-line targeted therapy. However, several researchers are working towards improvement of knowledge for this mutation to overcome the problem of resistance.
Key Findings
According to DelveInsight BRAF Mutated NSCLC market in the 7MM is expected to change during the study period 2017–2030.The therapeutic market of BRAF Mutated NSCLC in seven major markets was found to be USD 273 million in 2017 which is expected to increase during study period (2017–2030).
The United States: Market Outlook
In 2017, the total market size of BRAF Mutated NSCLC therapies was found to be USD 164 million in the United States which is expected to increase in the study period (2017–2030).
EU-5 Countries: Market Outlook
In 2017, the total market size of BRAF Mutated NSCLC therapies was found to be USD 103 million in the EU-5 countries which is expected to increase in the study period (2017–2030).
Japan Market Outlook
The total market size of BRAF Mutated NSCLC therapies in Japan was found to be USD 7.0 million in 2017.
The drugs which are in pipeline include:
1. Braftovi (encorafenib) plus Mektovi (binimetinib) (Pfizer): Phase II
2. Enfortumab Vedotin (Astellas Pharma/ Seattle Genetics): Phase II
Whole list of emerging products will be provided in the report...
Due to the monopoly of Tafinlar/Mekinist combo in the market and better clinical profile, this combo is expected to take major share among all the therapies for BRAF mutated NSCLC. However, due to expected launch of emerging therapies the Tafinlar/Mekinist combo sales is expected to be affected during the study period (2017–2030).
To keep up with current market trends, we take KOLs and SME’s opinion working in BRAF Mutated NSCLC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or BRAF Mutated NSCLC market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the BRAF Mutated NSCLC Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
• Patient Population
• Therapeutic Approaches
• BRAF Mutated NSCLC Pipeline Analysis
• BRAF Mutated NSCLC Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
• 11 Years Forecast
• 7MM Coverage
• BRAF Mutated NSCLC Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers
Market Insights:
Epidemiology Insights:
What is BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
The BRAF gene encodes for a serine/threonine kinase that belongs to the RAS-RAF-MEK-ERK axis regulating cellular growth. BRAF mutated NSCLC is now a rare form of lung cancer. The biologic behavior of BRAF mutated lung tumors tends to be more aggressive and resistant to chemotherapy.
What is BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market size in the 7 major markets (MM) in 2017?
The market size of BRAF mutated NSCLC in 7MM was USD 273 million in 2017.
What was the total incident cases of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) mutation in the 7MM in 2017?
The total incident cases of BRAF mutated NSCLC in the 7MM was 19,275 in 2017.
What are the market drivers of BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
Increase the use of biomarker testing, an increase in the mutation-specific trial activity and an increase in the disease incidence are the market drivers of BRAF Mutated NSCLC.
What are the market barriers of BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
The cost-effectiveness of therapies, small patient populations, cost of therapies, and disease burden are the market barriers of BRAF Mutated NSCLC.
Which are the emerging therapies in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market?
Vemurafenib Plus Cobimetinib, Braftovi (encorafinib) + Mektovi (binimetinib) are the emerging therapies in the BRAF Mutated NSCLC market.
Which are the leading companies in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market?
Hoffmann-La Roche, Pfizer are the leading companies in the BRAF Mutated NSCLC market.
How is epidemiology segmented for BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
The epidemiology segmentation of BRAF Mutated NSCLC is segmented as Total Incident Cases of NSCLC patients, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total Incident Cases of BRAF NSCLC, and Treated Patient Pool of BRAF NSCLC in 7MM from 2017 to 2030.
1. Key Insight
2. Executive Summary of BRAF Mutated NSCLC
3. SWOT Analysis of BRAF Mutated NSCLC
4. BRAF NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country
5. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total Incident cases of BRAF Mutated NSCLC in the United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total Incident cases of BRAF Mutated NSCLC in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total Incident cases of BRAF Mutated NSCLC in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total Incident cases of BRAF Mutated NSCLC in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total Incident cases of BRAF Mutated NSCLC in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total Incident cases of BRAF Mutated NSCLC in the United Kingdom
9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total Incident cases of BRAF Mutated NSCLC in Japan
10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Socity for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. Marketed Therapies
15. Key Cross
15.1. Tafinlar(Dabrafenib) in Combination with Mekinist(Trametinib): Novartis
15.1.1. Product Description
15.1.2. Regulatory Milestones
15.1.3. Other Developmental Activities
15.1.4. Pivotal Clinical Trials
16. Emerging Therapies
16.6. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
16.6.1. Product Description
16.6.2. Clinical Development
16.6.3. Safety and Efficacy
16.7. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
16.7.1. Product Description
16.7.2. Clinical Development
17. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
17.1. Key Findings
17.2. Market Outlook: 7MM
18. BRAF Mutation - Market Size
18.1. Total Market Size of BRAF NSCLC in the 7MM
18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM
18.3. United States Market Size
18.3.1. Total Market size of BRAF NSCLC in the United States
18.4. EU-5 Market Size
18.4.1. Germany Market Size
18.4.2. France Market Size
18.4.3. Italy Market Size
18.4.4. Spain Market Size
18.4.5. United Kingdom Market Size
18.5. Japan Market Size
18.5.1. Total Market size of BRAF NSCLC in Japan
20. Market Access and Reimbursement of BRAF Mutated NSCLC Therapies
21. Market Drivers of BRAF Mutated NSCLC
22. Market Barriers of BRAF Mutated NSCLC
23. Appendix
23.1. Bibliography
24. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
List of Tables:
Table 1 Summary of BRAF Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)
Table 34 Standard Treatment Options of NSCLC (Stage-wise)
Table 35 Summary of Recommendations (SEOM Clinical Guideline)
Table 36 Strength of Evidence
Table 37 Strength of Evidence
Table 38 Marketed Drugs Key Cross
Table 39 Vemurafenib Plus Cobimetinib, Clinical Trial Description, 2020
Table 40 Braftovi (encorafinib) + Mektovi (binimetinib), Clinical Trial Description, 2020
Table 41 Enfortumab vedotin, Clinical Trial Description, 2020
Table 42 7MM Market Size of BRAF NSCLC in USD Million (2017–2030)
Table 43 7MM Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 44 7MM Market Size of BRAF NSCLC by therapies, in USD Million (2017–2030)
Table 45 United States Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 46 United States Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 47 Germany Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 48 Germany Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 49 France Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 50 France Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 51 Italy Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 52 Italy Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 53 Spain Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 54 Spain Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 55 United Kingdom Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 56 United Kingdom Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 57 Japan Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 58 Japan Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 59 National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies
List of Figures:
Figure 1 BRAF NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)
Figure 46 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 47 Timeline Illustrating the Development of Targeted Therapies and Immunotherapies for the Treatment of NSCLC Over two decades
Figure 48 Immune Checkpoint Inhibitor
Figure 49 Unmet Needs
Figure 50 Market Size of BRAF NSCLC in the 7MM Countries in USD Million (2017–2030)
Figure 51 Market Size of BRAF NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 52 Market Size of BRAF NSCLC by therapies in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size of BRAF NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 54 Market Size of BRAF NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 55 Market Size of BRAF NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 56 Market Size of BRAF NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 57 Market Size of BRAF NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 58 Market Size of BRAF NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 59 Market Size of BRAF NSCLC by Therapies in Japan, in USD Millions (2017–2030)
Figure 60 Market Drivers
Figure 61 Market Barriers
